Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a letter
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI113267

Quantitation of the pathways of hepatic glycogen formation on ingesting a glucose load.

I Magnusson, V Chandramouli, W C Schumann, K Kumaran, J Wahren, and B R Landau

Department of Clinical Physiology, Karolinska Institute at Huddinge Hospital, Stockholm, Sweden.

Find articles by Magnusson, I. in: JCI | PubMed | Google Scholar

Department of Clinical Physiology, Karolinska Institute at Huddinge Hospital, Stockholm, Sweden.

Find articles by Chandramouli, V. in: JCI | PubMed | Google Scholar

Department of Clinical Physiology, Karolinska Institute at Huddinge Hospital, Stockholm, Sweden.

Find articles by Schumann, W. in: JCI | PubMed | Google Scholar

Department of Clinical Physiology, Karolinska Institute at Huddinge Hospital, Stockholm, Sweden.

Find articles by Kumaran, K. in: JCI | PubMed | Google Scholar

Department of Clinical Physiology, Karolinska Institute at Huddinge Hospital, Stockholm, Sweden.

Find articles by Wahren, J. in: JCI | PubMed | Google Scholar

Department of Clinical Physiology, Karolinska Institute at Huddinge Hospital, Stockholm, Sweden.

Find articles by Landau, B. in: JCI | PubMed | Google Scholar

Published December 1, 1987 - More info

Published in Volume 80, Issue 6 on December 1, 1987
J Clin Invest. 1987;80(6):1748–1754. https://doi.org/10.1172/JCI113267.
© 1987 The American Society for Clinical Investigation
Published December 1, 1987 - Version history
View PDF
Abstract

Diflunisal, 5-(2',4'-difluorophenyl)salicylic acid, excreted in urine as its glucuronide, was given to normal humans (n = 6) along with a glucose load specifically labeled with 14C. Glucuronide excreted by each subject was reduced to its glucoside and glucose from it degraded to yield the distribution of 14 C in its six carbons. Randomization of the 14C from the specifically labeled glucose was taken as a measure of the extent to which glucose was deposited indirectly (i.e., glucose----lactate----glucose----6-P----glycogen), rather than directly (i.e., glucose----glucose-6-P----glycogen). The maximum contribution to glycogen formation by the direct pathway was estimated to be 65 +/- 1%, on the assumption that glucuronide and glycogen are derived from the same hepatic pool of glucose-6-P in liver. Evidence that supports that assumption was obtained by comparing the randomization of 14C in the urinary glucuronide with that in glucose in blood from the hepatic vein of four of the subjects before and after they were given glucagon. Other evidence supporting the assumption was obtained by comparing in two subjects 3H/14C ratios in glucose from hepatic vein blood before and after glucagon administration with that in urinary glucuronide, having labeled the uridine diphosphate (UDP)-glucose in their livers with 14C by giving them 1-[14C]galactose and their circulating glucose with 3H by giving a 5-[3H]glucose-labeled load. It is concluded that glucuronide formation in humans can be used to trace glucose metabolism in the liver, and that in humans the indirect pathway of glucose metabolism is active.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1748
page 1748
icon of scanned page 1749
page 1749
icon of scanned page 1750
page 1750
icon of scanned page 1751
page 1751
icon of scanned page 1752
page 1752
icon of scanned page 1753
page 1753
icon of scanned page 1754
page 1754
Version history
  • Version 1 (December 1, 1987): No description

Article tools

  • View PDF
  • Download citation information
  • Send a letter
  • Share this article
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts